Treating Pulmonary Fibrosis with Non-Viral Gene Therapy: From Bench to Bedside.

ABSTRACT: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by irreversible lung scarring, which achieves almost 80% five-year mortality rate. Undeniably, commercially available pharmaceuticals, such as pirfenidone and nintedanib, exhibit certain effects on improving the well-being of IPF patients, but the stubbornly high mortality still indicates a great urgency of developing superior therapeutics against this devastating disease. As an emerging strategy, gene therapy brings hope for the treatment of IPF by precisely regulating the expression of specific genes. However, traditional administration approaches based on viruses severely restrict the clinical application of gene therapy. Nowadays, non-viral vectors are raised as potential strategies for in vivo gen

SUBMITTER: Huang T 

PROVIDER: S-EPMC9027953 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature